Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 10/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20008953 | 0.81 | KDM4E (0.35) | SMYD3HSD11B1LMNA | |
| SCHEMBL18081193 | 0.80 | SMYD3 (0.41) | SMYD3KCNH2 | |
| SCHEMBL18081294 | 0.78 | SMYD3 (0.39) | SMYD3HSD11B1MAPT | |
| SCHEMBL20012484 | 0.77 | SMYD3 (0.41) | SMYD3MAPT | |
| SCHEMBL27331243 | 0.76 | SMYD3 (0.46) | SMYD3MAPTKCNH2 | |
| SCHEMBL27326276 | 0.76 | SMYD3 (0.46) | SMYD3MAPTKCNH2 | |
| SCHEMBL27393947 | 0.76 | SMYD3 (0.46) | SMYD3MAPTKCNH2 | |
| SCHEMBL20009061 | 0.74 | TP53 (0.41) | HSD11B1LMNA | |
| SCHEMBL18133469 | 0.74 | TP53 (0.41) | HSD11B1LMNA | |
| SCHEMBL20009002 | 0.74 | TP53 (0.41) | HSD11B1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10308614-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308614-B2 | Therapeutic compounds and uses thereof | SMARCC1, SMARCC2, SMARCA4 | SMYD3 1086/4885HSD11B1 2021/4885MAPT 2011/4885 |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | SMARCC1, SMARCC2, SMARCA4 | SMYD3 1086/4885HSD11B1 2021/4885MAPT 2011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.